Assessment
Venous blood samples were collected for analysis of nemonoxacin PK at
predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, and 72 h postdose. Urine
sample was collected at predose and in the following postdose intervals:
0-4, 4-8, 8-12, 12-24, 24-48, and 48-72 h.
Safety was evaluated by examining the prevalence and severity of
adverse events (AEs), vital signs,
laboratory tests (hematology, clinical chemistry, and urinalysis),
physical examination, and 12-lead ECG. The final follow-up visit was
conducted at 72 h after administration of nemonoxacin.